Fully Human mAb Blocks SARS-CoV-2 Infection in Cultured Cells

Researchers say they have identified a fully human monoclonal antibody that prevents the SARS-CoV-2 virus from infecting cultured cells. The discovery, published today in Nature Communications, is an initial step toward developing a fully human antibody to treat or prevent COVID-19.

"This research builds on the work our groups have done in the past on antibodies targeting the SARS-CoV that emerged in 2002/2003," said Berend-Jan Bosch, co-lead author of the study. "Using this collection of SARS-CoV antibodies, we identified an antibody that also neutralizes infection of SARS-CoV-2 in cultured cells. Such a neutralizing antibody has potential to alter the course of infection in the infected host, support virus clearance or protect an uninfected individual that is exposed to the virus."

Dr. Bosch noted that the antibody binds to a domain that is conserved in both SARS-CoV and SARS-CoV-2, explaining its ability to neutralize both viruses. "This cross-neutralizing feature of the antibody is very interesting and suggests it may have potential in mitigation of diseases caused by future-emerging related coronaviruses."

"This discovery provides a strong foundation for additional research to characterize this antibody and begin development as a potential COVID-19 treatment," said Frank Grosveld, PhD. co-lead author on the study. "The antibody used in this work is 'fully human,' allowing development to proceed more rapidly and reducing the potential for immune-related side effects."